Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1277-1280

  Fish, Douglas N ^a   Abraham, Edward ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLARITHROMYCIN DERIVATIVE; DRUG METABOLITE;

ADULT; AGED; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG TOLERABILITY; FEMALE; HUMAN; INTENSIVE CARE; INTRANASAL DRUG ADMINISTRATION; LUNG ABSCESS; MALE; MENINGIOMA; NOSE FEEDING; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032905249     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1277     Document Type: Article

References (23)

1. Amodio-Groton, M., A. Madu, C. N. Madu, L. L. Briceland, M. Seligman, P. McMaster, and M. H. Miller. 1996. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Ann. Pharmacother. 30:596-602.
2. Bodenham, A., M. P. Shelly, and G. R. Park. 1988. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin. Pharmacokinet. 14:347-373.
3. Chu, S.-Y., L. T. Sennello, and R. C. Sonders. 1992. Simultaneous determination of clarithromycin and 14-R-hydroxyclaritnromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 571:199-208.
4. Chu, S.-Y., D. S. Wilson, D. R. P. Guay, and C. Craft. 1992. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J. Clin. Pharmacol. 32:1045-1049.
5. Chu, S.-Y., D. S. Wilson, R. L. Deaton, A. V. Mackenthun, C. N. Eason, and J. H. Cavenough. 1993. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 33:719-726.
6. Cockroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. Eliopoulos, G. M., E. Reiszner, M. J. Ferraro, and R. C. Moellering. 1988. Comparative in vitro activity of A-56268 (TE-031), a new macrolide antibiotic. J. Antimicrob. Chemother. 21:671-675.
8. Ferrero, J. L., B. S. Bopp, K. C. Marsh, S. C. Quigley, M. J. Johnson, D. J. Anderson, J. E. Lamm, K. G. Tollman, S. C. Sanders, J. H. Cavenough, and R. C. Sonders. 1990. Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 18:441-446.
9. File, T. M., Jr., J. Segreti, L. Dunbar, R. Player, R. Kohler, R. R. Williams, C. Kojak, and A. Rubin. 1997. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41:1965-1972.
10. Fish, D. N., and E. Abraham. 1996. Pharmacokinetics of clarithromycin (CL) suspension administered via nasogastric tube (NGT) in critically ill patients, abstr. A79, p. 16. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Floyd-Reising, S., J. A. Hindler, and L. S. Young. 1987. In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. Antimicrob. Agents Chemother. 31: 640-642.
12. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
13. Hardy, D. J., D. M. Hensey, J. M. Beyer, C. Vojtko, E. J. McDonald, and P. B. Fernandez. 1988. Comparative activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32:1710-1719.
14. Hardy, D. J., R. N. Swanson, R. A. Rode, K. Marsh, N. L. Shipkowitz, and J. J. Clement. 1990. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob. Agents Chemother. 34:1407-1413.
15. Hardy, D. J., D. R. P. Guay, and R. N. Jones. 1992. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. Diagn. Microbiol. Infect. Dis. 15:39-53.
16. Jorgensen, J. H., L. A. Maher, and A. W. Howell. 1991. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. Antimicrob. Agents Chemother. 35:1524-1526.
17. Nathwani, D., A. Boyter, P. G. Fegan, and P. Davey. 1996. Switch therapy in community-acquired pneumonia. Arch. Intern. Med. 156:1235-1237.
18. Paladino, J. A., H. E. Sperry, J. M. Backes, J. A. Gelber, D. J. Serrianne, T. J. Cumbo, and J. J. Schentag. 1991. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am. J. Med. 91:462-470.
19. Piscitelll, S. C., L. H. Danziger, and K. A. Rodvold. 1992. Clarithromycin and azithromycin: new macrolide antibiotics. Clin. Pharm. 11:137-152.
20. Ramirez, J. A., L. Srinath, S. Ahkee, A. Huang, and M. J. Raff. 1995. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. 155: 1273-1276.
21. Ritchie, D. J., A. W. Hopefl, T. W. Milligan, J. E. Byrne, and M. S. Maddox. 1993. In vitro activity of clarithromycin, cefprozol, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens. Clin. Ther. 15:107-113.
22. Vance, E., M. Watson-Bitar, L. Gustavson, and P. Kazanjian. 1995. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob. Agents Chemother. 39:1355-1360.
23. Vogel, F. 1995. Sequential therapy in the hospital management of lower respiratory tract infections. Am. J. Med. 99(Suppl. 6B):S14-S19.